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Abstract
Problem: As	antiphospholipid	antibody‐positive	women	with	adverse	pregnancy	out‐




Method of study: Plasma	 levels	of	C5a	and	C5b‐9	complement	components	of	43	
APS	non‐pregnant	patients	and	17	pregnant	APS	women	were	measured	using	en‐
zyme‐linked	 immunosorbent	 assay.	 The	 results	 were	 compared	 with	 those	 of	 16	
healthy	 non‐pregnant	 women	 and	 eight	 healthy	 pregnant	 women,	 respectively.	
Placenta	samples	of	five	APS	patients	at	high	risk	of	pregnancy	complications	and	of	
five healthy controls were subjected to immunoblotting analysis with specific anti‐
bodies	to	C5b‐9	and	CD46,	CD55,	CD59	complement	regulators.
Results: The	mean	plasma	C5a	and	C5b‐9	levels	were	significantly	higher	in	the	non‐
pregnant	APS	patients	with	previous	thrombosis	±	pregnancy	morbidity	(P = .0001 
and P	=	.0034,	respectively)	and	in	the	pregnant	APS	women	with	adverse	outcomes	
(P	=	.0093	for	both).	Similarly,	C5b‐9	amounts	were	significantly	higher	in	the	adverse	
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1  | INTRODUC TION
Antiphospholipid	syndrome	(APS)	is	an	autoimmune	disease	charac‐
terized by thrombosis and/or pregnancy morbidity associated to the 
presence in the blood of antiphospholipid antibodies (aPL), such as 






gestation due to eclampsia or severe preeclampsia, or recognized fea‐
tures	of	placental	insufficiency,	and/or	(c)	three	or	more	unexplained	
consecutive	spontaneous	abortions	before	the	10th	week	of	gesta‐







prevent its proinflammatory and destructive capabilities. Complement 
regulators	and	specifically	membrane‐bound	regulator	proteins	CD46,	
CD55, and CD59 control the three major complement activation path‐
ways	and	inactivate	both	C3	and	C5b‐9	terminal	complex.2
Complement‐mediated	placental	inflammation	has	been	found	to	
play	a	key	 role	 in	experimental	models	of	 fetal	 loss.3,4 While there 
appears to be an increase in the deposition of C4d in the placentas of 
antiphospholipid‐positive	women,	no	corresponding	 increase	 in	the	
deposition of C3 or its split products has been reported.5‐7 Data on 
the	amounts	of	complement	component	C5b‐9	and	on	the	expression	
of complement regulatory proteins in the placenta are, instead, con‐
troversial or insufficient.5,7,8 While lower serum C3 and/or C4 com‐
plement protein levels have been found in almost half of 201 women 
with	obstetric	APS9 and they seem to be independent predictors of 
lower neonatal birth weight and of births at an earlier gestational 
age,10 a subsequent study failed to uncover any associations between 
hypocomplementemia and obstetric complications.11 More recently, 
since	increased	plasma	Bb	and	C5b‐9	activation	product	levels	have	
been	 reported	 in	 antiphospholipid‐positive	 women	 with	 adverse	
pregnancy outcomes, it can be hypothesized that complement acti‐
vation contributes to the pathogenesis of this clinical condition.12








consensus statement criteria, were collected.1	 A	 control	 group	
of	 16	 healthy	 non‐pregnant	 women	 and	 eight	 healthy	 pregnant	
women	age‐matched	with	 the	 two	study	groups	was	considered.	
Placenta	samples	were	collected	 from	five	APS	patients	and	 five	
age‐matched	 healthy	 controls.	 The	 study	 was	 approved	 by	 the	
Ethics	 Committee	 for	 Clinical	 Trials	 of	 the	 Provinces	 of	 Verona	
and Rovigo (Italy) and was carried out in accordance with the 1964 
Declaration	of	Helsinki	and	 its	 later	amendments,	or	comparable	
ethical standards. Written informed consent was obtained from all 
the participants.
2.2 | Sample collection
In order to minimize any potential bias, confounder, or other source 
of variability, the plasma and placenta samples of the patients and 
controls were processed by the same operator and the laboratory 
materials such as precast gels and monoclonal antibodies that were 
used were from the same production lot.
A	venous	blood	(10	mL)	was	taken	from	the	non‐pregnant	APS	
patients	 at	 the	 time	 of	 diagnosis,	 from	 the	 pregnant	 APS	women	
with a favorable outcome during the first trimester of pregnancy 
and from those with adverse pregnancy outcome at the time of 
pregnancy	complications.	The	samples	were	collected	in	pre‐cooled	
VACUETTE® tubes containing 0.015 mol/L sodium citrate (Greiner 
Bio‐One	 GmbH)	 and	 centrifuged	 immediately	 at	 4°C.	 The	 plasma	
was separated from the cells by centrifugation at 3000 g for 15 min‐
utes	 at	 4°C.	 The	 plasma	 samples	 were	 then	 aliquoted	 in	 1.5	 mL	
Eppendorf	microtubes	 (Sigma‐Aldrich®)	 and	 stored	 at	 −80°C	 until	
use.	Analysis	was	carried	out	on	samples	thawed	only	once.	The	pla‐
centas were collected immediately after delivery, cleaned with a pH 
7.4	phosphate	buffer	solution,	and	kept	on	 ice.	All	 the	tissue	sam‐
ples were handled using sterile gloves, forceps and a scalpel under a 
biohazard	hood.	Pieces	of	placentas	weighing	approximately	200	mg	





Plasma	 concentrations	 of	C5a	 and	 soluble	C5b‐9	were	 assessed	
using	 the	MicroVue	 C5a	 Plus	 EIA	 (QUIDEL®) and the MicroVue 
C5b‐9	 Plus	 EIA	 (QUIDEL®), respectively, following the manufac‐
turer's instructions. In accordance with the manufacturer sugges‐
tions	plasma	samples	were	assayed	for	C5a	and	C5b‐9	detection	
using	a	1:20	and	1:10	dilutions,	 respectively.	The	optical	density	
was measured in a microtiter plate reader at 450 nm using the 
TECAN	Sunrise	 III	 (Tecan).	The	concentrations,	expressed	as	ng/










The	 proteins	were	 extracted	 from	 the	 placenta	 specimens	 by	 ho‐
mogenizing the tissues in 2 mL of Lysis Buffer (1.5 mmol/L MgCl2, 




vortexed	 for	2	minutes,	 three	 times,	 to	complete	cell	 lysis.	Finally,	





electrophoresis	 in	 SDS‐(12%)	 Mini‐PROTEAN®	 TGX	 Stain‐Free™	
precast	polyacrylamide	gel	(Bio‐Rad)	under	both	reducing	and	non‐
reducing	 conditions	 and	 then	 blotted	 to	 a	 PVDF	membrane	 using	
the	Mini	Trans‐Blot®Cell	(Bio‐Rad).	The	membranes	were	incubated	
with	blocking	buffer	(3%	w/v	BSA	in	Tris‐Buffered	Saline	and	0.1%	
v/v	Tween‐20)	and	 then	probed	with	each	of	 the	 four	monoclonal	
primary	anti‐human	antibodies	(Abcam):	1:1000	anti‐human	C5b‐9,	
1:5000	 anti‐human	 CD46,	 1:25	 000	 anti‐human	 CD55,	 1:50	 000	
anti‐human	CD59	shook	overnight	at	4°C.	As	certified	by	the	manu‐
facturer all antibodies used to detect the complement components 
were	verified	antibodies.	The	immunocomplexes	were	detected	by	
chemiluminescence using the ECL Plus Western Blotting Detection 
Reagents	 (GE	Healthcare	 Life	Biosciences/Amersham	Biosciences)	
after	 they	were	washed	and	 incubated	with	1:15	000	HRP‐conju‐
gated	 anti‐rabbit	 antibody	 (Abcam)	 or	 1:5000	 HRP‐linked	 anti‐
mouse	antibody	(Abcam)	for	1	hour	at	22°C.	Images	were	acquired	
using	 the	 Image	Quant	Las	Mini	4000	Digital	 Imaging	System	 (GE	
Healthcare	 Life	 Sciences),	 adjusting	 the	 exposure	 time	 depending	
on	 the	 intensity	 of	 the	protein	bands.	 The	blots	were	 stripped	by	
adding a stripping acid solution made in our laboratory (50 mmol/L 
glycine,	1%	w/v	SDS,	1%	w/v	Tween‐20;	pH	2.2	with	HCl),	shook	for	
30	minutes	at	37°C,	and	re‐incubated	with	1:500	anti‐human	ß‐tu‐
bulin antibodies to confirm the equal sample loading of the gels and 





IgG/IgM	 anticardiolipin	 and	 IgG/IgM	 anti‐β2Glycoprotein I en‐
zyme‐linked	 immunosorbent	 assay	 (ELISA)	 were	 performed	 using	
a	 home‐made	method	 following	 the	 European	 Forum	on	 aPL	 rec‐
ommendations, described elsewhere.13	A	series	of	sera	traceable	to	
the Harris standard sera were used as the calibration curves for the 
IgG/IgM	 anticardiolipin	 antibodies.	 The	 results	 were	 expressed	 in	
GPL	and	MPL	units.	A	home‐made	standard	curve	obtained	from	a	
pool	of	positive	samples	calibrated	to	Koike's	monoclonal	antibodies	
(HCAL	for	IgG	and	EY2C9	for	IgM	anti‐β2Glycoprotein I antibodies) 
was	used	 to	detect	 IgG/IgM	anti‐β2Glycoprotein	 I	 antibodies.	The	
results	were	expressed	in	arbitrary	units.	The	cutoff	values	for	the	
medium‐high	 levels	 of	 IgG/IgM	 anticardiolipin	 and	 IgG/IgM	 anti‐
β2Glycoprotein I antibodies were calculated as >the 99th percen‐
tile using sera from 100 healthy women. Lupus anticoagulant was 
assessed by means of multiple coagulation tests carried out using 
platelet‐poor	plasma	samples	following	updated	guidelines	and	uti‐
lizing dilute Russell viper venom and dilute activated partial throm‐
boplastin times as the screening tests.14
2.6 | Statistical analysis
The	 mean	 plasma	 levels	 of	 C5a	 and	 C5b‐9	 complement	 compo‐
nents	 in	 the	 non‐pregnant	 APS	 and	 pregnant	 APS	 patients	 were	
compared	with	 those	 in	 the	 non‐pregnant	 and	 pregnant	 controls,	
respectively,	using	a	nonparametric	Mann‐Whitney	U	test.	The	same	
test	was	used	to	compare	the	mean	 levels	of	C5b‐9,	CD46,	CD55,	
CD59	amounts	 in	 the	placentas	of	 the	APS	patients	with	 those	of	
the	 healthy	 controls,	 in	 the	 placentas	 of	APS	patient	with	 favora‐
ble outcome with those with adverse outcome and in the placentas 
of	APS	patients	with	involvement	of	chorionic	villi	only	with	those	
with involvement of both villi and decidua vessels. In particular, the 
means of the results obtained from the three different placenta por‐
tions	of	APS	women	were	compared	with	those	of	the	placentas	of	
the	healthy	controls.	A	P	<	.05	value	was	considered	statistically	sig‐
nificant. Statistical analyses were performed using GraphPad Prism 
statistical software.
3  | RESULTS
3.1 | The demographic and clinical data of the APS 
patients




were divided into two groups on the basis of their pregnancy out‐
come:	Ten	had	a	favorable	outcome	with	a	mean	week	at	delivery	of	
36.6	±	2.2	and	a	mean	birth	weight	of	2702	g	±	516;	seven	had	an	
adverse pregnancy outcome characterized by premature birth as‐
sociated to severe pregnancy complications including preeclampsia 
in three cases (one leading to neonatal death), intrauterine growth 
restriction	in	two,	catastrophic	APS	in	one,	and	hemolysis	elevated	
liver enzymes, and low platelet count (HELLP) syndrome in one. 
According	 to	 the	 Miyakis'	 laboratory	 categories,1 among women 
with	 favorable	pregnancy	outcome	six	were	 in	category	 I	 (two	or	
more antiphospholipid antibodies), while four in category II (one 
only	 antiphospholipid	 antibody).	 All	 seven	 patients	 with	 adverse	
outcome were in category I.
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The	five	APS	patients	whose	placentas	were	studied	had	a	mean	
age	of	36.8	±	2.8	SD,	their	laboratory	and	clinical	characteristics	are	
reported	 in	 Table	 1.	Given	 the	 presence	 of	 previous	 severe	 preg‐
nancy complications, in two cases associated to vascular throm‐
bosis, and to positivity to all the antiphospholipid antibody assays 
(triple	positivity),	they	were	all	considered	at	high	risk	of	pregnancy	
complications.15	 Four	 had	 a	 favorable	 pregnancy	 outcome	 with	
a	mean	week	at	delivery	of	35.0	±	2.4	and	a	mean	birth	weight	of	
2582	g	±	495;	one	suffered	from	premature	birth	due	to	intrauterine	
growth restriction and oligohydramnios.
All	the	APS	patients	participating	in	the	study	were	treated	with	
prophylactic	 or	 therapeutic	 doses	 of	 low‐molecular	 weight	 hep‐




were	 considered	 at	 high	 risk	 for	 pregnancy	 complications16 were 
treated, in addition to conventional therapy as follows: one (patient 
no.5)	with	low‐dose	steroids	plus	hydroxychloroquine	starting	at	the	
positive	pregnancy	test	and	four	with	weekly	plasma	exchange	plus	
a fortnightly intravenous immunoglobulin bolus starting from the 
detection of fetal heartbeat.17
3.2 | Complement studies on the plasma samples
As	 indicated	 in	 Table	 2	 and	 Figure	 1,	 the	 mean	 plasma	 level	 of	
complement	 anaphylatoxin	 C5a	was	 significantly	 higher	 in	 the	 43	
non‐pregnant	 APS	 patients	 considered	 together	 with	 respect	 the	
non‐pregnant	healthy	controls.	The	most	significant	difference	was	
observed	in	the	patients	with	previous	thrombosis	±	pregnancy	mor‐
bidity.	As	 far	 as	 the	pregnant,	APS	patients	were	 concerned,	only	
those with adverse outcomes showed a significant prevalence of 
C5a	with	respect	to	the	pregnant	control	women.	The	mean	plasma	
C5a	 levels	 of	 the	 non‐pregnant	 APS	 women	 with	 previous	 preg‐
nancy	morbidity	alone	and	the	pregnant	APS	patients	with	favorable	
outcomes were not significantly different from those of the healthy 
controls.	Similarly,	 the	mean	plasma	C5b‐9	 levels	significantly	pre‐





3.3 | Complement studies on the placentas
The	normalized	placental	amounts	of	C5b‐9,	CD46,	CD55,	and	CD59	
in	APS	patients	vs	healthy	controls	 and	 in	patients	with	 favorable	
pregnancy outcome vs that with adverse outcome have been re‐
ported	in	Table	4	and	5,	respectively.	The	mean	C5b‐9	terminal	com‐
plex	 amount	 level	was	 significantly	 higher	 in	 the	 placentas	 of	 the	
APS	women	considered	together	with	respect	to	that	in	the	controls	
(Table	 4).	 The	mean	C5b‐9	 terminal	 complex	 amount	 level	 signifi‐
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patient with respect to that in the patients with favorable outcomes 
(Table	5).	Conversely,	the	mean	CD46,	CD55,	and	CD59	complement	
regulator amount values were lower, even if significantly only CD59, 
in	the	placentas	of	all	the	APS	women	with	respect	to	those	of	the	
controls	(Table	4),	and	in	the	placentas	of	APS	patients	with	adverse	
outcome, even if significantly only CD55, with respect to those of 
APS	patients	with	favorable	outcome	(Table	5).	Representative	pic‐
tures	 of	 the	 normalized	 placental	 amounts	 of	 C5b‐9	 complement	
complex	 and	 complement	 regulators	 in	 APS	 patients	 vs	 healthy	
controls and in patients with favorable pregnancy outcome vs that 
with	adverse	outcome	are	shown	 in	Figures	3	and	4,	 respectively.	
Furthermore,	 Figure	 5	 shows	 all	 plots	 of	 Western	 immunoblot‐
ting	analysis	of	the	placentas	of	APS	patients	and	healthy	controls	
concerning	the	C5b‐9	terminal	complex,	the	complement	regulators	
and the respective β‐tubulins.
The	 anatomo‐pathologic	 data	 of	 the	 placentas	 (Table	 1)	 were	
subdivided into two categories: involvement of chorionic villi only 




the placentas with involvement of both villi and decidua vessels than 
in those with villus involvement only (4.8 vs 3.2) and lower mean 
values of all complement regulators in the placentas with involve‐
ment of both villi and decidua vessels compared to those with villus 
involvement	only	(CD46	1.7	vs	13.4,	CD55	4.0	vs	12.1,	CD59	1.0	vs	




Mean ± SD P
Non‐pregnant	APS	
patients
43 16 11.9	±	6.3 6.0	±	2.9 .0007* 
With previous preg‐
nancy morbidity




67.4% 16 13.4	±	6.1 6.0	±	2.9 .0001* 
Pregnant	APS	patients 17 8 12.9	±	7.8 7.8	±	2.9 .1535
With favorable 
outcome
58.8% 8 7.5	±	4.5 7.8	±	2.9 .7618
With adverse 
outcome
41.2% 8 19.3	±	7.2 7.8	±	2.9 .0093* 
Abbreviation:	APS,	antiphospholipid	syndrome.
*Significant	result.	
TA B L E  2   C5a complement component 
in maternal plasma of different subsets of 
APS	patients	and	healthy	controls
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2.5). However, CD46 and CD55 only were also significantly lower 
(P = .0016 for both).
4  | DISCUSSION
The	 current	 analysis	 uncovered	 significantly	 higher	 mean	 plasma	
complement	activation	C5a	and	C5b‐9	component	levels	in	the	most	
severe	 APS	 subset	 characterized	 by	 a	 history	 of	 vascular	 throm‐
bosis	±	pregnancy	morbidity,	a	profile	which	is	often	associated	to	
poor pregnancy outcomes when conventional heparin/aspirin ther‐
apy is used.16	The	mean	C5a	and	C5b‐9	levels	 in	the	patients	with	
previous pregnancy morbidity alone, whose profile is generally as‐
sociated with a favorable pregnancy outcome during conventional 
treatment,16 were not significantly different with respect to those 
of	healthy	control	women.	High	plasma	C5a	and	C5b‐9	levels	would	
seem,	in	this	context,	to	be	predictive	markers	of	adverse	pregnancy	
outcome during conventional treatment.
Study	 data	 showed	 that	 only	 the	 pregnant	 APS	 patients	 with	
adverse pregnancy outcome characterized by severe pregnancy 
complications (preeclampsia, intrauterine growth restriction, cata‐
strophic	APS	and	HELLP	syndrome)	who	were	unresponsive	to	con‐
ventional treatment had significantly higher mean plasma C5a and 
C5b‐9	levels	with	respect	to	the	healthy	controls.	As	an	activation	




Mean ± SD P
Non‐pregnant	APS	
patients









67.4% 16 410.2	±	382.1 170.8	±	92.0 .0034* 
Pregnant	APS	
patients
17 8 430.0	±	398.9 229.6	±	92.2 .2104
With favorable 
outcome
58.8% 8 214.7	±	134.1 229.6	±	92.2 .6334
With adverse 
outcome
41.2% 8 693.9	±	502.0 229.6	±	92.2 .0093* 
Abbreviation:	APS,	antiphospholipid	syndrome
*Significant	result.	
TA B L E  3  C5b‐9	complement	complex	
in maternal plasma of different subsets of 
APS	patients	and	healthy	controls






     |  7 of 10SCAMBI et Al.
of complement cascade seemed to be present in these patients and 
given their severe clinical conditions, treatments prescribed in ad‐
dition to conventional therapy, which currently include intravenous 
immunoglobulins,	low‐dose	steroids,	plasma	exchange	and	hydroxy‐
chloroquine,	could	be	administered,	 taking	 into	account	 their	anti‐
complement	activity	and	potential	side‐effects.17
In the effort to obtain reliable results, the current study mea‐
sured the complement components for three different portions 
of the placentas. Mirroring the results obtained for the plasma 
samples,	the	mean	C5b‐9	placenta	amount	level	significantly	pre‐
vailed in the adverse pregnancy outcome patient with respect to 
those in the women with favorable outcomes and thus confirmed 
TA B L E  4  Normalized	placental	amounts	of	C5b‐9	complement	complex	and	complement	regulators	in	APS	patients	and	healthy	controls




Mean ± SD P
C5b‐9 5 5 4.17	±	2.42 1.68	±	0.95 .0037* 
CD46 5 5 6.45	±	8.76 14.2	±	20.43 .062
CD55 5 5 7.24	±	5.1 16.7	±	13.45 .081




TA B L E  5  Normalized	placental	amounts	of	C5b‐9	complement	complex	and	complement	regulators	in	APS	patients	according	to	
pregnancy outcome




Mean ± SD P
C5b‐9 4 1 3.47	±	2.2 6.95	±	0.20 .0115* 
CD46 4 1 7.52	±	9.6 2.18	±	0.93 .516
CD55 4 1 8.70	±	4.65 1.49	±	0.52 .0115* 




F I G U R E  3  Levels	of	C5b‐9,	CD46,	
CD55, and CD59 in patients with 
antiphospholipid	syndrome	(APS)	and	
in	healthy	controls	(HC).	The	amount	




correspond to the values from the 
lower to upper quartiles and medians, 
respectively
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that there is more complement activation in the presence of 
severe pregnancy complications. Only two studies have inves‐
tigated	C5b‐9	 amount	 in	 the	 placenta	 thus	 far.	 In	 the	 first,	 the	
presence	of	C5b‐9	in	APS	placentas	was	significantly	lower	or	not	
significantly different from that found in control placentas.5 In 
the	 second,	 C5b‐9	 deposits	were	 found	 on	 the	 surface	 of	 syn‐
cytiotrophoblast with additional distribution on the intervillous 
fibrin	 in	 the	 placentas	 of	 APS	 patients	 but	 not	 in	 those	 of	 the	
controls.8	As	 the	pregnancy	outcomes	were	 reported	 in	neither	
of	 the	 studies,	 it	 is	 impossible	 to	 verify	 if	 the	 C5b‐9	 placental	
expression	was	higher	 in	 the	placentas	of	 the	APS	women	with	
adverse pregnancy outcomes.
In accordance to another report,8 we observed signs of comple‐
ment	activation	in	both	the	plasmas	and	placentas	of	pregnant	APS	
women	although	being	treated	with	heparin,	known	for	its	capacity	
to	 inhibit	 complement	 activation	 and	 to	 prevent	 complement‐me‐
diated	 pregnancy	 loss	 in	 a	 mouse	 model	 of	 obstetric	 APS.18	 The	
placentas	 of	 our	 APS	 patients	 showed	 a	 significant	 deposition	 of	
C5b‐9	 terminal	 complex	and	a	decrease	 in	complement	 regulators	
with respect to the placentas of healthy controls, thus, the important 








correspond to the values from the 
lower to upper quartiles and medians, 
respectively
F I G U R E  5  All	plots	of	Western	




(CD46, CD55, and CD59) and the 
respective β‐tubulins
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complement	activation	in	APS	patients	could	have	overwhelmed	the	
potential direct inhibitory effects of heparin on the complement 
cascade.	 A	 correlation	 between	 placental	 pathologic	 features	 and	
complement deposition (C4d) in the trophoblastic cytoplasm, cell 
membrane, and basement membrane has been demonstrated in 
placentas	of.aPL‐positive	women.5 It is possible that the binding of 
complement activation products to restricted placental areas may 
cause tissue alterations that marginally affect the regular progres‐
sion of pregnancy, instead a widespread placental involvement could 
be associated to adverse outcome of pregnancy.
The	mean	complement	CD46,	CD55,	and	CD59	regulator	levels	
were lower, although only CD59 was significantly reduced, in the 
placentas	of	all	the	APS	women	studied,	independently	of	the	preg‐
nancy	 outcome,	with	 respect	 to	 those	 of	 the	 controls.	 The	 lower	
CD46,	CD55,	 and	CD59	placenta	expressions	 in	APS	patients	 can	
impair local protection, promoting complement hyperactivation and 
consequently leading to inflammation, thrombosis and tissue dam‐
age. In fact, lower levels of CD46, CD55, and CD59 regulator was 
found, although only CD55 was significantly reduced, in the placen‐




developed preeclampsia.19 However, as the difference in the mean 
complement	regulator	levels	between	the	APS	and	the	control	pop‐




investigated by another study using the same Western blot analysis 
for their detection.20	As	the	authors	found	significantly	higher	levels	
of CD46 and CD55 proteins (P	<	.001	for	both)	in	the	placentas	of	
the	APS	patients	with	respect	to	those	in	the	controls,	they	hypoth‐
esized that there is a mechanism which increases CD46 and CD55 
expression	 in	placentas	 as	 an	effect	of	 the	proinflammatory	 cyto‐
kines	present	 in	APS	 thrombophilia.20	The	 level	of	 risk	 in	 the	APS	
women was, unfortunately, not specified by the authors of the study. 
In our case, the history of severe pregnancy complications and the 
presence of triple antiphospholipid positivity that characterized all 
our	patients	made	them	all	at	high	risk	of	pregnancy	complications.17 
One, in fact, developed adverse pregnancy outcome despite addi‐
tional	treatment	with	low‐dose	steroids	and	hydroxychloroquine.
Concerning the correlation between placental histology and com‐
plement/protein	deposition,	APS	placentas	with	a	more	 severe	his‐
tology (chorionic villus and decidual vessel involvement) had higher 
C5b‐9	complex	and	lower	complement	regulator	mean	amounts	than	
those	with	less	severe	anatomo‐pathological	lesion	(villus	involvement	
only). In addition, levels of CD46 and CD55 deposition were also sig‐
nificantly	lower	in	placentas	with	more	severe	histology.	These	data,	
even if obtained in a small number of cases, could further support the 
role	of	the	complement	in	the	obstetrical	complications	of	the	APS.
Clearly,	 this	 study's	 primary	 limit	 is	 linked	 to	 the	 low	 number	
of cases studied, while its strength lies in the homogeneity of the 
results demonstrating that the activation of the complement cas‐
cade	in	both	the	pregnant	and	non‐pregnant	APS	patients	was	asso‐
ciated to severe clinical conditions.
5  | CONCLUSIONS
A	 heparin/aspirin	 combination	 constitutes	 the	 conventional	 treat‐
ment	protocol	for	pregnant	APS	women.	As	these	strategies	fail	 in	





ments in the effort to improve live birth rates and/or reduce preg‐
nancy complications.22
In	 the	 future,	 if	 these	 results	 are	 confirmed	 by	 further	 large‐
scale studies, it will become possible to identify those patients in 
whom	 complement	 inhibitors	 are	 likely	 to	 prevent	 or	 modify	 the	
inflammatory‐related	 sequelae	 associated	with	 adverse	 pregnancy	
outcomes.	Detection	of	high	plasma	C5b‐9	complex	and	C5a	levels	
in	APS	women	could	be	considered	predictive	or	 the	first	signs	of	
adverse pregnancy outcome and lead to the decision to prescribe a 
targeted treatment. Eculizumab, a humanized monoclonal antibody 
that binds to the C5 component of complement and inhibits termi‐
nal	complement	activation,	 for	example,	could	 represent	one	such	
possibility.	Prescribed	 to	 two	pregnant	patients	at	high	 risk	of	de‐
veloping	devastating	APS‐related	complications,	it	was	found	to	be	
a safe treatment option throughout the rest of the pregnancy.23,24 
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